Circulating tumour cells: Insights into tumour heterogeneity

Journal of Internal Medicine

Volumn 274, Issue 2, 2013, Pages 137-143

  Hayes, D F ^a   Paoletti, C ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Circulating tumor cells; Tumor heterogeneity

Indexed keywords

ANDROGEN RECEPTOR; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; EVEROLIMUS; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BCL 2; SOMATOMEDIN; TAMOXIFEN;

BIOPSY; BREAST CANCER; BREAST METASTASIS; CANCER CELL POPULATION HETEROGENEITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CHROMOSOMAL INSTABILITY; CIRCULATING TUMOR CELL; DISTANT METASTASIS; ENVIRONMENTAL STRESS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE QUALITY; HUMAN; MEDICAL PARAMETERS; METASTASIS; MICROMETASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERTANT; REVIEW; SYSTEMIC THERAPY; TREATMENT RESPONSE;

CIRCULATING TUMOR CELLS; TUMOR HETEROGENEITY;

BIOPSY, NEEDLE; BREAST NEOPLASMS; FEMALE; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84880378159     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12047     Document Type: Review

References (53)

1. Schnipper L. Clinical implications of tumor-cell heterogeneity. N Engl J Med 1986; 314: 1423-32.
2. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
3. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348: 2431-42.
4. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005; 353: 1734-6.
5. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
6. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-33.
7. Norton L. Implications of kinetic heterogeneity in clinical oncology. Semin Oncol 1985; 12: 231-49.
8. Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of potential anticancer agents. XII. On the criteria and kinetics associated with curability of experimental leukemia. Cancer Chemother Rep 1964; 35: 1-111.
9. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
10. Early Breast Cancer Trialists Collaborative Group T. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100, 000 women in 123 randomized trials. Lancet 2012; 379: 432-44.
11. Hull DF 3rd, Clark GM, Osborne CK, Chamness GC, Knight WA 3rd, McGuire WL. Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983; 43: 413-6.
12. Lindstrom LS, Karlsson E, Wilking UM et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012; 30: 2601-8.
13. Allegra JC, Barlock A, Huff KK, Lippman ME. Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer 1980; 45: 792-4.
14. Wu JM, Fackler MJ, Halushka MK et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 2008; 14: 1938-46.
15. Wicha MS. Cancer stem cell heterogeneity in hereditary breast cancer. Breast Cancer Res 2008; 10: 105.
16. Cardoso F, Di Leo A, Larsimont D et al. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 2001; 12: 615-20.
17. Guidi AJ, Berry DA, Broadwater G et al. Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst 2000; 92: 486-92.
18. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-9.
19. Ellis M, Hayes DF, Lippman ME. Treatment of metastatic breast cancer. In: Harris J, Lippman M, Morrow M, Osborne CK, eds. Diseases of the Breast. Philadelphia: Lippincott Williams & Wilkins, 2004; 1101-62.
20. Kennedy BJ. Endocrine therapy of breast cancer. J Am Med Assoc 1967; 200: 971-2.
21. Fidler IJ, Hart IR. Biological diversity in metastatic neoplasms: origins and implications. Science 1982; 217: 998-1003.
22. Curtis C, Shah S, Chin S-F et al. The genomic and transcriptomic architecture of 2, 000 breast tumors reveals novel subgroups. Nature 2012; 486: 346-52.
23. Shah SP, Roth A, Goya R et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486: 395-9.
24. Ellis MJ, Ding L, Shen D et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486: 353-60.
25. Ding L, Ellis MJ, Li S et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464: 999-1005.
26. Bayliss J, Hilger A, Vishnu P, Diehl K, El-Ashry D. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res 2007; 13: 7029-36.
27. Gee JM, Robertson JF, Gutteridge E et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 2005; 12(Suppl. 1): S99-111.
28. Hayes E, Nicholson RI, Hiscox S. Acquired endocrine resistance in breast cancer: implications for tumour metastasis. Front Biosci 2011; 16: 838-48.
29. Gilani RA, Kazi AA, Shah P et al. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat 2012; 135: 681-92.
30. Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 1869; 14: 146-9.
31. Paoletti C, Smerage J, Hayes DF. Circulating tumor cells as a marker of prognosis. Princip Prac Oncol 2012; 26: 1-8.
32. Rack B, Schindlbeck C, Andergassen U et al. Use of circulating tumor cells in peripheral blood of breast cancer patients before and after adjuvant chemotehapy to predict increased risk for relapse: the SUCCESS trial. Proc Am Soc Clin Oncol 2010; 28: 114s (Abstract #1003).
33. Lucci A, Hall CS, Lodhi AK et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012; 13: 688-95.
34. Rack B, Schindlbeck C, Andergassen U et al. Prognostic role of circulating tumor cells in the peripheral blood of primary breast cancer patients. Cancer Res 2010; 24(suppl): 93 (abstract S6-5).
35. Hayes DF, Cristofanilli M. Re: anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009; 101: 894-5 author reply 6-7.
36. Haagensen CD. Diseases of the Breast. Philadelphia: W.B. Saunders, 1971.
37. Braun S, Marth C. Circulating tumor cells in metastatic breast cancer - toward individualized treatment? N Engl J Med 2004; 351: 824-6.
38. Meng S, Tripathy D, Frenkel EP et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004; 10: 8152-62.
39. Wiedswang G, Borgen E, Karesen R et al. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 2004; 10: 5342-8.
40. Wicha MS, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol 2011; 29: 1508-11.
41. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009; 119: 1417-9.
42. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-8.
43. Paoletti C, Connelly M, Chianese D et al. Development of Circulating Tumor Cell-Endocrine Therapy Index in metastatic breast cancer patients. Clinical Cancer Research Proceedings of the San Antonio Breast Cancer Symposium 2011; 24(suppl): 451s (abst. p4-07-016).
44. Neubauer H, Clare SE, Wozny W et al. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res 2008; 10: R85.
45. Fehm T, Krawczyk N, Solomayer EF et al. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res 2008; 10: R76.
46. Fehm T, Becker S, Duerr-Stoerzer S et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 2007; 9: R74.
47. Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011; 17: 3903-12.
48. Pecot CV, Bischoff FZ, Mayer JA et al. A novel platform for detection of CK+ and CK- CTCs. Cancer Discov 2011; 1: 580-6.
49. Powell AA, Talasaz AH, Zhang H et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS ONE 2012; 7: e33788.
50. Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359: 366-77.
51. Pestrin M, Bessi S, Puglisi F et al. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat 2012; 134: 283-9.
52. Armstrong AJ, Eisenberger MA, Halabi S et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol 2012; 61: 549-59.
53. Hayes DF, Walker TM, Singh B et al. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 2002; 21: 1111-7.